On Jun. 11, 2020, Quidel announced it had received funding from the Biomedical Advanced Research and Development Authority (ﾓBARDAﾔ), to support development of a point-of-care diagnostic assay that potentially tests for four respiratory viruses: SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus.